Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Th1902 and 5-FU resistance in colorectal cancer treatment

<< Previous

Bullboard Posts

Next >>

Post by jeffm34on Jul 21, 2022 1:38am

297 Views

Post# 34839451

Th1902 and 5-FU resistance in colorectal cancer treatment

TH1902 may be the answer in 5-FU resistant colorectal cancer treatment.

https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.15752

After 72 hours of 5-FU treatment, we did not observe any effect on TrkB and p75NTR expression (Figure 1SC). However, a significant enhancement of sortilin expression was observed in both cell lines

In this study, sortilin is overexpressed in vitro after 5-FU treatments whether short (72 hours) or long (one month) and also in in vivo-treated tumours. Elevated SORT1 mRNA expression was associated with poorer survival, DFS and RFS in high-risk CRC patients. Its overexpression is also associated with high CRC grades. These findings provide the first evidence that sortilin is a biomarker of 5-FU resistance in CRC, which is associated with poorer prognosis and clinical outcomes, and higher tumour grades.

<< Previous

Bullboard Posts

Next >>

Quebecor achieves all Freedom Mobile acquisition commitments